Optimizing Cell Therapy Products with IsoPlexis® Proteomics and Excellos: Starting Material and Manufacturing Characterization

Discover novel strategies to monitor and improve metabolic markers of cAPI content in cellular therapy products.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

Factors contributing to clinical outcome variability.
CAR-T immunotherapy progression.
Effector/Memory function-API considerations.
cAPI manufacturing challenges and how to overcome them.
A Deeper Look

More about this

Optimizing Cell Therapy Products with IsoPlexis® Proteomics and Excellos

Cell therapies are a paradigm shift in medicine, already demonstrating remarkable results in a variety of indications with numerous clinical trials ongoing or planned in the near term.

Despite these promising results, this class of therapeutics can be further optimized to garner even greater clinical benefit. Some key aspects for further improvement include better characterization of the potency and durability of cells from donors, starting materials, manufacturing intermediates, and final products manufactured.

Download this eBook to explore case studies and learn more.

awards-bar-3-wide-color-right
awards-bar-4-wide-color-left
Get the